Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK.
Breast Cancer Res Treat. 2019 Jul;176(1):37-52. doi: 10.1007/s10549-019-05235-7. Epub 2019 Apr 17.
Treatments for breast cancer can lead to chronic musculoskeletal problems. This study aimed to systematically review the evidence surrounding the cost-effectiveness of exercise and physiotherapy interventions aimed at reducing the risk of physical symptoms and functional limitations due to breast cancer treatment.
A systematic review of the cost-effectiveness of exercise and physiotherapy interventions during and following treatment for breast cancer was undertaken according to PRISMA guidelines. Literature searches were carried out in Ovid MEDLINE, Ovid Embase, Web of Science, EconLit, CINAHL, PsycINFO, Scopus and the Cochrane Library. Cost-effectiveness evidence was summarised in a descriptive manner and studies were assessed using quality appraisal tools. The review protocol was registered on PROSPERO.
A total of 7783 articles were identified and seven were included in the final review. Five studies undertook trial-based economic evaluations, whereas two studies conducted economic evaluation based on decision models. One study was a cost-effectiveness analysis (CEA), three undertook stand-alone cost-utility analyses (CUA) and three studies were combined CEAs and CUAs. Three studies reported favourable cost-effectiveness results for different exercise or physiotherapy interventions. In contrast, four studies found that exercise and physiotherapy interventions were not cost-effective on the basis of quality-adjusted life year outcomes.
The evidence surrounding the cost-effectiveness of exercise and physiotherapy interventions for the treatment of breast cancer remains sparse with contrasting conclusions. Future research should particularly aim to broaden the evidence base by disentangling the contributing effects of frequency, intensity, time and type of exercise and physiotherapy interventions on cost-effectiveness outcomes.
乳腺癌的治疗可能会导致慢性肌肉骨骼问题。本研究旨在系统地回顾针对减少因乳腺癌治疗而导致的身体症状和功能障碍风险的运动和物理治疗干预措施的成本效益的证据。
根据 PRISMA 指南,对运动和物理治疗干预措施在乳腺癌治疗期间和之后的成本效益进行了系统评价。在 Ovid MEDLINE、Ovid Embase、Web of Science、EconLit、CINAHL、PsycINFO、Scopus 和 Cochrane Library 中进行了文献检索。以描述性方式总结成本效益证据,并使用质量评估工具评估研究。该综述方案已在 PROSPERO 上注册。
共确定了 7783 篇文章,最终有 7 篇文章纳入了最终综述。五项研究进行了基于试验的经济评估,而两项研究则基于决策模型进行了经济评估。一项研究是成本效益分析(CEA),三项研究进行了独立的成本效用分析(CUA),三项研究是 CEA 和 CUA 的结合。三项研究报告了不同运动或物理治疗干预措施的有利成本效益结果。相比之下,四项研究发现运动和物理治疗干预措施在基于质量调整生命年结果方面没有成本效益。
针对乳腺癌治疗的运动和物理治疗干预措施的成本效益证据仍然稀缺,结论相互矛盾。未来的研究应特别旨在通过厘清运动和物理治疗干预措施的频率、强度、时间和类型对成本效益结果的影响,来扩大证据基础。